Treatment of lentigo maligna with tazarotene 0.1% gel

Sergio Chimenti, Anna Maria Carrozzo, Luigi Citarella, Catia De Felice, Ketty Peris

Research output: Contribution to journalArticlepeer-review


We report 2 elderly patients with facial lentigo maligna who experienced complete regression, both clinically and histopathologically, after once-daily topical treatment with tazarotene 0.1% gel for 6 to 8 months. After a follow-up period of 18 and 30 months, no recurrence was observed. We believe that tazarotene might be considered as an alternative medical approach in selected patients with lentigo maligna.

Original languageEnglish
Pages (from-to)101-103
Number of pages3
JournalJournal of the American Academy of Dermatology
Issue number1
Publication statusPublished - Jan 2004

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Treatment of lentigo maligna with tazarotene 0.1% gel'. Together they form a unique fingerprint.

Cite this